Roche

AZ’s Imfinzi plus tremelimumab combo misses again

The data for Imfinzi is nevertheless still a plus overall for AZ as it allows it to challenge Roche’s PD-L1 inhibitor Tecentriq (atezolizumab), which was approved for first-line ... Both Roche and AZ will however be looking over their shoulders at

20 for 2020 – Five pharma leaders to watch in 2020

Analysts think the deal could catapult Galapagos into the top tier of biopharma companies, joining the likes of Regeneron, Biogen and Roche’s Genentech unit, providing its pipeline delivers as hoped

Novo Nordisk hits pause on rival to Hemlibra for haemophilia

Concizumab is a potential rival to Roche’s blockbuster Hemlibra (emicizumab), the first non-clotting factor therapy for haemophilia A to reach the market, although it targets a different part of ... Roche’s drug has transformed the treatment of

CEPI says $2bn is needed for COVID-19 vaccine development

instead. The warning comes after China approved the use of Roche's anti-inflammatory drug Actemra (tocilizumab) for the treatment of COVID-19 patients who experience lung complications.

Sanofi, Regeneron launch trials of arthritis drug Kevzara for COVID-19

The announcement comes close on the heels of China’s approval of Roche’s rival IL-6 inhibitor Actemra (tocilizumab) for the treatment of coronavirus patients with lung complications. ... treatment with Roche’s drug.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]